3D Systems (DDD) Q3 2025: Cost Actions Target $50M Savings as Dental and MedTech Backlogs Build
3D Systems’ third quarter reflected continued macro-driven demand softness but also early traction in new dental and MedTech launches, with cost actions on track for over $50 million in annualized savings by year end. Strategic divestitures and targeted R&D investment signal a sharpened focus on high-consumption, high-margin product lines, while backlog in key dental and industrial verticals points to improving revenue visibility into 2026.
Summary
- Dental and MedTech Pipeline: Backlog builds in jetted dentures and trauma implants signal future growth.
- Cost Structure Reset: Facility exits and operating cuts drive progress toward positive cash flow.
- Industrial Partnerships Expand: Saudi and Lockheed Martin ventures diversify end-market exposure.
Performance Analysis
3D Systems’ Q3 results were shaped by persistent macro headwinds, with revenue declines concentrated in consumer-facing industrial and dental segments, as customers continued to defer capital expenditures amid tariff uncertainty. The company’s $91.2 million in consolidated revenue marked a 14% year-over-year decline excluding divested assets, with sequential softness reflecting typical seasonality and the absence of a prior quarter regenerative medicine milestone. Industrial Solutions, the larger segment at $48 million, saw a 4.5% YoY decline excluding Geomagic, while Healthcare Solutions fell 22% due to dental customer order timing, partially offset by MedTech’s 8% YoY growth and robust performance in personalized health services (PHS).
Gross margin compressed to 33% from 38% last year, primarily driven by lower sales volume and an unfavorable mix shift, compounded by manufacturing variances and inventory clean-up. Operating expenses fell 24% YoY, reflecting the impact of ongoing cost reduction initiatives, with management reiterating that further expense cuts are expected through the first half of 2026. Adjusted EBITDA was negative, but improved by $3.5 million versus the prior year, and cash burn moderated, supported by a $114 million cash balance and reduced CapEx needs going forward.
- Industrial Segment Resilience: Aerospace and defense grew nearly 50% YoY, offsetting consumer market weakness.
- Dental Stabilization: Aligner demand volatility appears to be bottoming, while jetted dentures ramp.
- Cost Reductions Materialize: OpEx down sharply, with $50 million in annualized savings targeted by year end.
Execution on cost, divestitures, and targeted R&D investment is creating a leaner, more focused business, positioning 3D Systems to benefit from recovery in delayed capital spending and adoption of new high-consumption applications.
Executive Commentary
"We've taken aggressive actions to adjust our cost structure while maintaining core R&D investments to position the company for long-term growth when market conditions improve... We've already begun to accept orders for this new printer platform, which, given the size of this global market, we expect to accelerate rapidly in the quarters ahead."
Dr. Jeffrey Graves, President and Chief Executive Officer
"We continue to demonstrate strong cost management in the quarter... To date, we are on track to deliver over $50 million in annualized savings by year end. As we look ahead to the fourth quarter and the first half of next year, our cost savings initiatives will be closely aligned to the company's strategic priorities for 2026."
Phyllis Nordstrom, Interim Chief Financial Officer
Strategic Positioning
1. Dental and MedTech Growth Engines
3D Systems is doubling down on dental and MedTech as its next major revenue streams, leveraging proprietary jetting technology and regulatory expertise. The commercial launch of NextDent jetted dentures in the US—offering multi-material, monolithic dentures produced faster and at lower cost than traditional methods—has begun to build a backlog with leading labs, with management targeting a billion-dollar market opportunity as regulatory approvals expand globally. In MedTech, the company’s printed polyether ether ketone (PEEK, a biocompatible implant material) is gaining traction in trauma and reconstructive applications, with rapid production cycles opening new use cases in both planned and emergency surgeries.
2. Industrial Diversification and Partnerships
Industrial Solutions is being repositioned toward high-reliability, high-value verticals, such as aerospace, defense, and energy infrastructure. The Saudi Arabian joint venture NAMI has secured strategic investments and orders—including a $26 million framework agreement for tungsten core components and a new Lockheed Martin collaboration for local defense manufacturing—demonstrating early success in the company’s international expansion and digital warehousing ambitions.
3. Cost Structure and Asset Rationalization
Management is executing a multi-year cost reset, with facility exits, organizational streamlining, and the divestiture of non-core software assets (Octon and 3DEXPERT) to focus on proprietary, high-consumption product lines. These actions are intended to align the business for profitability at lower revenue levels, with OpEx expected to decline further and positive cash flow targeted in a normalized demand environment.
4. R&D and Product Innovation
Despite cost cuts, core R&D investment remains protected, with focus on next-generation printers and materials that drive recurring consumables revenue. The launch of the MJP300W+ for jewelry and continued innovation in SLA (stereolithography) and SLS (selective laser sintering) platforms are designed to pull through high-margin materials consumption, supporting future gross margin expansion as installed base grows.
5. Capital Allocation Discipline
CapEx requirements are set to fall well below historical averages, as prior investments have built out necessary infrastructure. Management indicated CapEx could run less than half of the long-term 4% of sales benchmark over the next two years, freeing up cash for R&D and working capital as the recovery unfolds.
Key Considerations
3D Systems’ Q3 was marked by disciplined execution on cost and asset strategy, but also by clear signals that the company is positioning for a cyclical rebound and long-term secular adoption in digital manufacturing and personalized healthcare.
Key Considerations:
- Dental Market Inflection: Jetted dentures are moving from pilot to backlog, with regulatory expansion as the gating factor for global scale.
- Materials Pull-Through: New printer placements are expected to drive higher consumables revenue, supporting recurring margin lift.
- Cost Actions Not Fully Complete: Facility exits and remaining organizational streamlining will continue into early 2026, with timing risk around subleasing and lease expirations.
- Industrial Order Visibility: Large, multi-year agreements in Saudi Arabia and with Lockheed Martin diversify end markets but require local execution and technology validation.
- Cash Management: Reduced CapEx and moderated cash burn support liquidity, but sustained improvement hinges on margin recovery and top-line stabilization.
Risks
Macro-driven CapEx deferrals and tariff uncertainty remain key external risks, with customer caution limiting near-term revenue visibility across both industrial and dental segments. Execution risk persists around the timing of facility exits and the pace of regulatory approvals for new dental products. Competitive intensity in both additive manufacturing and digital dentistry could pressure pricing and adoption rates, while any delay in MedTech regulatory pathways would defer planned growth inflections.
Forward Outlook
For Q4, 3D Systems guided to:
- Revenue and gross margin reflecting the divestiture of Octon and 3DEXPERT, with a $1.2 million revenue and $1 million gross margin impact already included.
- Operating expenses targeted to be marginally below Q3 levels, with further cost reductions flowing through into early 2026.
For full-year 2025, management maintained a focus on cost discipline and backlog conversion, reiterating that:
- Annualized cost savings of over $50 million are expected to be realized by year end.
- Positive cash flow and profitability are targeted in a more normalized demand environment, with progress dependent on sales mix and margin recovery.
Management highlighted several factors that will shape results:
- Backlog build in dental and MedTech as regulatory approvals advance.
- Continued cost actions and facility exits to further lower OpEx through mid-2026.
Takeaways
3D Systems is executing a focused turnaround, balancing aggressive cost cuts with selective R&D investment and targeted bets in dental, MedTech, and industrial verticals.
- Backlog and pipeline in dental and trauma implants offer a path to growth, contingent on regulatory and customer adoption milestones.
- Cost structure reset is real, with OpEx and CapEx both moving lower, but execution risk remains as savings depend on facility exit timing and sales mix improvement.
- Investors should watch for conversion of dental and MedTech backlogs, continued progress on Saudi and defense partnerships, and margin recovery as new printer placements drive consumables pull-through in 2026.
Conclusion
3D Systems’ Q3 2025 marked a disciplined, if transitional, period—cost actions have begun to bear fruit, and strategic bets in dental and MedTech are building backlog for future growth. Execution on regulatory, customer adoption, and industrial partnerships will determine whether the company can translate its leaner model into sustainable profitability as end markets recover.
Industry Read-Through
3D Systems’ experience reflects broad-based CapEx caution across additive manufacturing, with customers deferring purchases due to macro and tariff uncertainty. However, the early ramp of digital dental and MedTech solutions, as well as multi-year industrial agreements in energy and defense, signal that secular adoption of 3D printing in high-value, highly regulated applications continues to advance. Competitors and adjacent players should note the importance of regulatory pathways, local execution in emerging markets, and the growing role of recurring consumables revenue as installed bases expand.